Akari Therapeutics Plc (AKTX): Total Liabilities
$19.56M
As of 2025-12-31
$20.03M
As of 2026-06-30
+17.6%
3-year compound annual growth
+30.2%
5-year compound annual growth
-0.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.56M | -30.9% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $28.33M | +518.1% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $4.58M | -61.9% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $12.04M | +97.6% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $6.09M | +16.7% | 2023-05-01, Balance as of period end |
| 2020-12-31 | $5.22M | n/a | 2022-05-16, Balance as of period end |
| 2020-09-30 | $6.75M | n/a | 2021-04-21, Balance as of period end |
| 2020-06-30 | $8.49M | n/a | 2021-04-21, Balance as of period end |
| 2020-03-31 | $6.41M | n/a | 2021-04-21, Balance as of period end |
| 2019-12-31 | $6.47M | n/a | 2021-04-21, Balance as of period end |
| 2019-09-30 | $5.37M | n/a | 2021-04-21, Balance as of period end |
| 2019-06-30 | $4.15M | n/a | 2021-04-21, Balance as of period end |
| 2019-03-31 | $3.39M | n/a | 2021-04-21, Balance as of period end |
| 2018-12-31 | $4.92M | -58.7% | 2020-03-31, Balance as of period end |
| 2017-12-31 | $11.90M | +1.1% | 2019-04-23, Balance as of period end |
| 2016-12-31 | $11.77M | -44.4% | 2018-07-18, Balance as of period end |
| 2015-12-31 | $21.17M | n/m | 2017-03-31, Balance as of period end |
| 2014-12-31 | $1.17M | n/a | 2016-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $19.56M | -30.9% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $8.26M | +66.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $22.39M | -65.0% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $18.94M | -21.9% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $5.00M | -67.6% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $15.24M | -1.0% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
Compare AKTX, ATOS, VTGN, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗